(Q37810986)

23 August 2017

The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins (English)

1 reference

23 August 2017

1 reference

Miao Hu

1

1 reference

23 August 2017

Kenneth K W To

series ordinal

2

1 reference

23 August 2017

Valiant W L Mak

series ordinal

3

1 reference

23 August 2017

Brian Tomlinson

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

23 November 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

49-62

1 reference

23 August 2017

1

1 reference

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Transporter pharmacogenetics and statin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Efflux and uptake transporters as determinants of statin response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Overview: ABC transporters and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Human ATP-binding cassette (ABC) transporter family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Pharmacogenomic importance of ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

A multidrug resistance transporter from human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Role of the breast cancer resistance protein (ABCG2) in drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

MicroRNAs play a role in the development of human hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

21 January 2018

ABCG2: a perspective.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Localisation of breast cancer resistance protein in microvessel endothelium of human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

The effects of cholesterol on learning and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Role reversal for anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Pheophorbide a is a specific probe for ABCG2 function and inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Extending the good diet, good health paradigm: modulation of breast cancer resistance protein (BCRP) by flavonoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Effect of silymarin supplement on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Single nucleotide polymorphisms modify the transporter activity of ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Functional analysis of SNPs variants of BCRP/ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

HMG-CoA reductase inhibitors and P-glycoprotein modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

APOE gene polymorphisms and response to statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Genomewide association analysis of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.538383

10.1517/17425255.2011.538383

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference